Table 2.

Antitumor activity of LY2835219 in subcutaneous human tumor xenografts

Xenograft model	Compound dose	Percent delta T/C, percent regression	P-Value	Day calculated
Colo-205 colorectal	100 mg/kg qdx21	0	<0.001	day 35
	50 mg/kg qdx21	28	<0.001	day 35
	25 mg/kg qdx21	52	<0.001	day 35
	PD0332991, 100 mg/kg qdx21	−1	<0.001	day 35
MV4-11 AML	100 mg/kg qdx21	−48	<0.001	day 49
	50 mg/kg qdx21	30	<0.001	day 49
	25 mg/kg qdx21	45	0.008	day 49
	PD0332991, 50 mg/kg qdx21	16	<0.001	day 49
U87 MG glioblastoma	100 mg/kg qdx21	1	<0.001	day 31
	50 mg/kg qdx21	33	<0.001	day 31
	25 mg/kg qdx21	49	0.001	day 31
	PD0332991, 50 mg/kg qdx21	26	<0.001	day 31
H460 lung	100 mg/kg qdx21	36	<0.001	day 35
	50 mg/kg qdx21	60	<0.001	day 35
	25 mg/kg qdx21	84	NS	day 35
	PD0332991, 50 mg/kg qdx21	60	<0.001	day 35
Colo-205 colorectal	12.5 mg/kg qd	53	0.087	day 39
	50 mg/kg q2d	27	0.003	day 39
	50 mg/kg qd	0	<0.001	day 39
	PD0332991, 50 mg/kg	7	<0.001	day 39
Calu-6 lung	50 mg/kg, qdx10	42	0.007	day 20
	50 mg/kg, qdx22	48	<0.001	day 34
Jeko1 MCL	100 mg/kg	10	<0.001	day 45
	PD0332991, 100 mg/kg	12	<0.001	day 45

100 % if treated volume = control volume

0 % if treated volume = baseline volume

−100 % if treated volume = zero

with linear interpolation between these points